EP0353290A4 - Selective inhibition of gene expression by photoactivatable oligonucleotides - Google Patents

Selective inhibition of gene expression by photoactivatable oligonucleotides

Info

Publication number
EP0353290A4
EP0353290A4 EP19890902442 EP89902442A EP0353290A4 EP 0353290 A4 EP0353290 A4 EP 0353290A4 EP 19890902442 EP19890902442 EP 19890902442 EP 89902442 A EP89902442 A EP 89902442A EP 0353290 A4 EP0353290 A4 EP 0353290A4
Authority
EP
European Patent Office
Prior art keywords
photoactivatable
oligonucleotides
gene expression
selective inhibition
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19890902442
Other versions
EP0353290A1 (en
Inventor
Francis P. Gasparro
Richard L. Edelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Chemex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemex Pharmaceuticals Inc filed Critical Chemex Pharmaceuticals Inc
Publication of EP0353290A1 publication Critical patent/EP0353290A1/en
Publication of EP0353290A4 publication Critical patent/EP0353290A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0066—Psoralene-activated UV-A photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens or fucocoumarins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
EP19890902442 1988-01-21 1989-01-23 Selective inhibition of gene expression by photoactivatable oligonucleotides Withdrawn EP0353290A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14657188A 1988-01-21 1988-01-21
US146571 1988-01-21
US29926589A 1989-01-20 1989-01-20
US299265 1989-01-20

Publications (2)

Publication Number Publication Date
EP0353290A1 EP0353290A1 (en) 1990-02-07
EP0353290A4 true EP0353290A4 (en) 1990-09-05

Family

ID=26844064

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19890902442 Withdrawn EP0353290A4 (en) 1988-01-21 1989-01-23 Selective inhibition of gene expression by photoactivatable oligonucleotides

Country Status (3)

Country Link
EP (1) EP0353290A4 (en)
AU (1) AU3056889A (en)
WO (1) WO1989006702A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE230023T1 (en) * 1990-08-14 2003-01-15 Isis Pharmaceuticals Inc INFLUENCE ON CELL ADHESION BY OLIGONUCLEOTIDES
IE914220A1 (en) * 1990-12-10 1992-06-17 Akzo Nv Labelled, modified oligonucleotides
US5733523A (en) * 1990-12-10 1998-03-31 Akzo Nobel N.V. Targeted delivery of a therapeutic entity using complementary oligonucleotides
IL101978A0 (en) * 1991-05-31 1992-12-30 Genta Inc Neutral oligomers capable of being delivered transdermally and across mucous membranes
IL105741A0 (en) * 1992-05-22 1993-09-22 Genta Inc Pharmaceutical compositions for treating cellular hyperproliferation using interleukin-1 inhibitory compounds
US6147056A (en) * 1995-06-06 2000-11-14 Trustees Of Boston University Use of locally applied DNA fragments
US20030032610A1 (en) * 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
DE19853425A1 (en) * 1998-11-19 2000-05-25 Martin Roecken Topical composition containing khellin or its derivatives, useful for phototherapy of psoriasis and eczema, has low mitogenic potential
DE10019252A1 (en) * 2000-04-18 2001-10-31 Klaus Karl Degitz Polydeoxyribonucleotides to inhibit ICAM-1 gene expression
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US9439897B2 (en) * 2007-11-06 2016-09-13 Immunolight, Llc Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0316016A2 (en) * 1987-11-12 1989-05-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modified oligonucleotides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599303A (en) * 1983-12-12 1986-07-08 Hri Associates, Inc. Nucleic acid hybridization assay employing probes crosslinkable to target sequences
US4582789A (en) * 1984-03-21 1986-04-15 Cetus Corporation Process for labeling nucleic acids using psoralen derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0316016A2 (en) * 1987-11-12 1989-05-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modified oligonucleotides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO8906702A1 *

Also Published As

Publication number Publication date
EP0353290A1 (en) 1990-02-07
WO1989006702A1 (en) 1989-07-27
AU3056889A (en) 1989-08-11

Similar Documents

Publication Publication Date Title
IL91049A0 (en) Method for the amplification of nucleotide sequences
EP0521108A4 (en) Site specific cleavage of single-stranded dna
AU3360289A (en) Method of sequencing dna
GB9514437D0 (en) Inhibition of gene expression
GB8926026D0 (en) Extended nucleotide sequences
HK62691A (en) 13-substituted derivatives of avermectin agylcones
AU6601690A (en) Selective inhibition of gene expression by photoactivatable oligonucleotides
AU4848793A (en) Oligonucleotide and nucleotide amine analogs, methods of synthesis and use
HU893412D0 (en) Inhibitors of interleucin-1
EP0353290A4 (en) Selective inhibition of gene expression by photoactivatable oligonucleotides
GB9007137D0 (en) Selective inhibition of dna polymerase
GB8901675D0 (en) Inhibitor of gene expression
HU9500979D0 (en) Antisense oligonucleotide inhibition of the ras gene
PL270981A1 (en) Pesticide containing novel derivatives of 2-phenylimidazole
GB2222164B (en) Nucleotide derivatives
EP0307730A3 (en) Expression of mutarotase
ZA904825B (en) Inhibition of potato-sprouting
PL273723A1 (en) Method of obtaining oligonucleotides
IE881594L (en) Derivatives of dideoxycytidine
GB8810675D0 (en) Inhibition of transferase activity
GB8809652D0 (en) Chemical process & intermediates
AU7302191A (en) Inhibition of transcription by double-stranded oligonucleotides
ZA891735B (en) Method of detecting nucleotide sequences
GB8827166D0 (en) Obtention & purification of rna
PL273565A1 (en) Method for purification of 1,4-denzodiazepine derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19891005

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19900718

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: YALE UNIVERSITY

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19930801